Kizilisik A T, Ray J B, Nylander W A, Langone A J, Helderman J H, Shaffer D
Veterans Administration Medical Center, Department of Surgery, Nashville, TN 37203, USA.
Exp Clin Transplant. 2004 Dec;2(2):238-41.
Advances in immunosuppressive therapy have led to substantial improvements in kidney transplant outcomes in the past 20 years. Kidney transplantation activity started in 1963 at the Veterans Administration Medical Center in Nashville, Tennessee, and continues to grow with increasing numbers of transplants from living-related and unrelated donors. In this study, patient and graft survival rates during 2 different periods were evaluated and compared with non-veterans-administration centers.
Six hundred fourteen kidney transplants were performed between March 1963 and December 2002. For analytic purposes, the 40-year experience was divided into 2 eras based on the immunosuppressive agents used. Azathioprine and prednisone were the immunosuppressive agents used in era 1. A calcineurin-inhibitor-based triple immunosuppressive regimen initially including azathioprine and prednisone and later, mycophenolate mofetil and prednisone, was the preferred immunosuppressive regimen in era 2.
In era 1, 1-year patient and graft survival rates were 72.5% and 50%, and 89% and 75% for deceased-donor and living-donor transplants respectively. In era 2, patient survival rates increased to 95.1% and 87.8% for 1 and 3 years respectively, while graft survival increased to 87.6% and 74.9%. Forty-three percent of deceased-donor and 21% of living-donor kidneys were lost owing to rejection in era 1. In era 2, the incidence of acute rejection was 14.5% overall.
Overall, our results are comparable with non-veterans-administration centers and the national average and show that kidney transplantation offers veteran patients with end-stage renal disease a safe and effective treatment with increased quality of life.
在过去20年中,免疫抑制疗法的进展使肾移植结果有了显著改善。1963年,田纳西州纳什维尔的退伍军人管理局医疗中心开始开展肾移植活动,并且随着来自亲属和非亲属活体供肾移植数量的增加,该活动持续发展。在本研究中,评估了两个不同时期的患者和移植物存活率,并与非退伍军人管理局中心进行了比较。
1963年3月至2002年12月期间共进行了614例肾移植。为便于分析,根据所使用的免疫抑制剂,将40年的经验分为两个时代。时代1使用硫唑嘌呤和泼尼松作为免疫抑制剂。时代2首选基于钙调神经磷酸酶抑制剂的三联免疫抑制方案,最初包括硫唑嘌呤和泼尼松,后来包括霉酚酸酯和泼尼松。
在时代1,1年患者和移植物存活率分别为72.5%和50%,死体供肾移植和活体供肾移植分别为89%和75%。在时代2,1年和3年患者存活率分别增至95.1%和87.8%,移植物存活率增至87.6%和74.9%。在时代1,43%的死体供肾和21%的活体供肾因排斥反应而丢失。在时代2,急性排斥反应的总体发生率为14.5%。
总体而言,我们的结果与非退伍军人管理局中心及全国平均水平相当,表明肾移植为患有终末期肾病的退伍军人患者提供了一种安全有效的治疗方法,提高了生活质量。